Rossari Biotech Announces Q1 FY26 Results: Revenues Up 11%, EBITDA Up 4.6%, PAT Down 3.7%

Rossari Biotech Limited, a Specialty-Chemicals manufacturer, has announced its financial results for the quarter ended June 30, 2025. The company reported a 11% YoY growth in revenues, a 4.6% YoY growth in EBITDA, but a 3.7% YoY reduction in PAT. The Home, Personal Care and Performance Chemicals (HPPC) and Animal Health and Nutrition (AHN) divisions achieved a healthy growth of 16% and 12% respectively. The company is confident that its continued efficiency initiatives and focused efforts on optimizing the product mix will drive growth over the coming quarters. The ongoing capacity expansion projects across verticals are expected to enhance manufacturing capabilities, improve supply chain agility, and strengthen the company's responsiveness to high-growth sectors.